Document is current
Any future updates will be listed below
-
Authors
Zhu, James https://orcid.org/0000-0003-2713-1839
Wang, Yunguan
Chang, Woo Yong https://orcid.org/0000-0002-7129-5016
Malewska, Alicia
Napolitano, Fabiana https://orcid.org/0000-0002-2463-8952
Gahan, Jeffrey C.
Unni, Nisha
Zhao, Min
Yuan, Rongqing
Wu, Fangjiang
Yue, Lauren
Guo, Lei
Zhao, Zhuo
Chen, Danny Z. https://orcid.org/0000-0001-6565-2884
Hannan, Raquibul
Zhang, Siyuan https://orcid.org/0000-0003-0910-3666
Xiao, Guanghua https://orcid.org/0000-0001-9387-9883
Mu, Ping
Hanker, Ariella B. https://orcid.org/0000-0002-8655-8341
Strand, Douglas
Arteaga, Carlos L.
Desai, Neil
Wang, Xinlei https://orcid.org/0000-0002-8561-6511
Xie, Yang https://orcid.org/0000-0001-9456-1762
Wang, Tao https://orcid.org/0000-0002-4355-149X
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP190208)
Cancer Prevention and Research Institute of Texas (RP230363)
Cancer Prevention and Research Institute of Texas (RR220024)
Cancer Prevention and Research Institute of Texas (RR170061)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA258584)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA255064)
U.S. Department of Health & Human Services | National Institutes of Health (RC2DK129994)
U.S. Department of Health & Human Services | National Institutes of Health (R01DK115477)
U.S. Department of Health & Human Services | National Institutes of Health (R01DK135535)
Dedman Family Scholars in Clinical Care
- License Information
-
More Information
Article History
Received: 24 January 2024
Accepted: 2 August 2024
First Online: 3 September 2024
Competing interests
: T.W. receives personal consulting fees from Merck for projects unrelated to this study. A.B.H. receives or has received research grants from Takeda and Lilly and non-financial support from Puma Biotechnology and Tempus. C.L.A. receives or has received research grants from Pfizer, Lilly and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. The other authors declare no competing interests.
